Drug intelligence / Profile preview

XC7

Development stage: Phase 1
Lead developer: NP Medical
Modality: Small Molecules
Administration: Oral

Overview

XC7 is a small molecule drug developed for infectious and respiratory diseases, particularly COVID-19. It underwent Phase 1 clinical trials in Russia that evaluated its safety, tolerability, and pharmacokinetics in healthy volunteers through both single and multiple dose administration.

Beyond the preview

Go deeper on XC7.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on XC7.

Explore the full profile